Publications by authors named "Shaun Goodman"

Claim this Profile
E
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.
Francesco Fioretti, Javed Butler, Jacob A Udell, W Schuyler Jones, Mark C Petrie, Shaun G Goodman

ESC Heart Fail· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
Sotirios Tsimikas, Michael Szarek, Christa M Cobbaert, Fred Romijn, J Wouter Jukema, Shaun G Goodman

Circulation· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism.
Davide Capodanno, John H Alexander, M Cecilia Bahit, John W Eikelboom, C Michael Gibson, Shaun G Goodman

Nat Rev Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial.
Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich, Sabina A Murphy, Shaun G Goodman

JAMA Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a) Levels and Time to Cardiovascular Benefit With Alirocumab in Patients With Recent Acute Coronary Syndrome.
Kausik K Ray, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Sergio Fazio, Shaun G Goodman

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.
Esther Reijnders, Patrick M Bossuyt, J Wouter Jukema, L Renee Ruhaak, Fred P H T M Romijn, Shaun G Goodman

Arterioscler Thromb Vasc Biol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trial.
Shahab Ghafghazi, Lynne Uhl, Brandon Herbert, Marnie Bertolet, John H Alexander, Shaun G Goodman

Transfusion· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of early revascularization in stable coronary artery disease with moderate or severe ischemia.
Ferdinand Jr Gerodias, Robert M Iwanochko, Peter C Austin, Xuesong Wang, Vladimír Džavík, Shaun G Goodman

Am Heart J Plus· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular-related hospital visits amongst oncology patients receiving immune checkpoint inhibitors: a population-based cohort study.
Wei Fang Dai, Steven Habbous, Andrew Yan, Husam Abdel-Qadir, Shaun G Goodman

J Cardiol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial.
Samer Al Said, Siddharth M Patel, Robert P Giugliano, David A Morrow, Erica L Goodrich, Shaun G Goodman

Circulation· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART.
Wade Thompson, Brendan Wong, Atul Sivaswamy, Laura Ferreira-Legere, Douglas S Lee, Shaun G Goodman

CJC Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asundexian or Apixaban in Patients With Atrial Fibrillation According to Prior Oral Anticoagulant Use: A Subgroup Analysis of the OCEANIC-AF Randomized Clinical Trial.
John H Alexander, Elizabeth J Lydon, Jonathan P Piccini, Thomas Viethen, Jonas Oldgren, Shaun G Goodman

JAMA Cardiol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Factor XI Inhibition and Periprocedural Bleeding: An Analysis From AZALEA-TIMI 71.
Siddharth M Patel, Robert P Giugliano, David A Morrow, Sanobar Parkar, Hannah Shapiro, Shaun G Goodman

J Am Coll Cardiol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of the GRACE risk score according to troponin elevation in patients admitted with non-ST elevation acute coronary syndrome: a post hoc analysis of the UKGRIS parallel group cluster randomised controlled trial.
Chris P Gale, Deborah Stocken, Ramesh Nadarajah, Suleman Aktaa, Catherine Reynolds, Shaun Goodman

Open Heart· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Implications of Machine Learning Algorithm-Supported Diagnostic Classification of Myocardial Injury Using the Fourth Universal Definition of Myocardial Infarction.
Kristina Lambrakis, Ehsan Khan, Zhibin Liao, Joey Gerlach, Adam J Nelson, Shaun G Goodman

Heart Lung Circ· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol Levels.
Sem A O F Rikken, C Michael Gibson, M Cecilia Bahit, Danielle Duffy, Gerald Chi, Shaun G Goodman

JACC Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized transfusion decisions to minimize adverse cardiovascular outcomes in patients with acute myocardial infarction and anemia.
Gerard T Portela, Gregory Ducrocq, Marnie Bertolet, John H Alexander, Shaun G Goodman

Am Heart J· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial.
Gregory G Schwartz, Michael Szarek, J Wouter Jukema, Christa M Cobbaert, Esther Reijnders, Shaun G Goodman

Diabetes Care· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Marat Fudim, Renato D Lopes, Daniel M Wojdyla, Roxana Mehran, Muhammad Shahzeb Khan, Shaun G Goodman

JACC Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.
Andrew M Goldsweig, William J Kostis, Brandon M Herbert, Claire Bouleti, Brian J Potter, Shaun G Goodman

Circ Heart Fail· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES.
P Gabriel Steg, Michael Szarek, J Wouter Jukema, Deepak L Bhatt, Vera A Bittner, Shaun G Goodman

Circulation· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guideline Directed Anticoagulant Treatment and Dosing in a Contemporary Atrial Fibrillation Cohort: Analysis of the TRANSECT-AF Program.
Cole Clifford, Shaun G Goodman, Mary K Tan, Jean Gregoire, Jeffrey Habert

CJC Open· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS.
Manasi Tannu, Renato D Lopes, Daniel M Wojdyla, Shaun G Goodman, Ronald Aronson

J Am Coll Cardiol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome.
Gregory G Schwartz, Michael Szarek, Esther Reijnders, J Wouter Jukema, Deepak L Bhatt, Shaun G Goodman

Eur J Prev Cardiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
Christian T Ruff, Siddharth M Patel, Robert P Giugliano, David A Morrow, Bruce Hug, Shaun G Goodman

N Engl J Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis